The effects of antipsychotic therapy on serum lipids: A comprehensive review

Schizophrenia Research

Volumn 70, Issue 1, 2004, Pages 1-17

  Meyer, Jonathan M ^a   Koro, Carol E ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Antipsychotics; Atypical; Cardiovascular risk; Cholesterol; Conventional; Hyperlipidemia; Lipids; Triglycerides

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE; CHLORPROMAZINE; CLOPENTHIXOL; CLOZAPINE; DIAZEPAM; FLUPERLAPINE; FLUPHENAZINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVOMEPROMAZINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOBARBITAL; PHENOTHIAZINE; PHENYTOIN; PROPRANOLOL; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIACYLGLYCEROL; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET; DRUG EFFECT; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; META ANALYSIS; METABOLIC ACIDOSIS; METABOLIC DISORDER; MONOTHERAPY; NEUROLOGICAL COMPLICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 3142769794     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.01.014     Document Type: Article

References (105)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 156:1999;1686-1696
2. Atmaca M., Kuloglu M., Tezcan E., Gecici O., Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr. Res. 60:2003;99-100
3. Atmaca M., Kuloglu M., Tezcan E., Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J. Clin. Psychiatry. 64:2003;598-604
4. Austin M.A. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am. J. Cardiol. 83:1999;13F-16F
5. Baptista T., Lacruz A., Angeles F., Silvera R., de Mendoza S., Mendoza M.T., Hernandez L. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry. 34:2001;223-231
6. Baymiller S.P., Ball P., McMahon R.P., Buchanan R.W. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr. Res. 59:2003;49-57
7. Beasley C.M. Jr., Tollefson G.D., Tran P.V. Safety of olanzapine. J. Clin. Psychiatry. 58:1997;13-17
8. Bell F.P., Hubert E.V. Inhibition of LCAT in plasma from man and experimental animals by chlorpromazine. Lipids. 16:1981;815-819
9. Bouchard R.H., Demers M.-F., Simoneau I., Almeras N., Villeneuve J., Mottard J.-P., Cadrin C., Lemieux I., Despres J.-P. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J. Clin. Psychopharm. 21:2001;110-111
10. Braun G.A., Paulonis M.E. Sterol metabolism: biochemical differences among the butyrophenones. Int. J. Neuropsychiatry. 3:1967;26-27. (Suppl.)
11. Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29:1999;697-701
12. Bustillo J.R., Buchanan R.W., Irish D., Breier A. Differential effect of clozapine on weight: a controlled study. Am. J. Psychiatry. 153:1996;817-819
13. Clark M.L., Johnson P.C. Amenorrhea and elevated serum cholesterol produced by a trifluoro-methylated phenothiazine. J. Clin. Endocrinol. Metabol. 20:1960;641-646
14. Clark M.L., Ray T.S., Paredes A., Ragland R.E., Costiloe J.P., Smith C.W., Wolf S. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosom. Med. 29:1967;634-642
15. Clark M.L., Braun G.A., Hewson J.R., Serafetinides E.A., Colmore J.P., Rahhal D.K. Trifluperidol and cholesterol in man. Clin. Pharmacol. Ther. 9:1968;333-340
16. Clark M., Dubowski K., Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin. Pharmacol. Ther. 11:1970;883-889
17. Clark M.L., Huber W.K., Sullivan J., Wood F., Costiloe J.P. Evaluation of loxapine succinate in chronic schizophrenia. Dis. Nerv. Syst. 33:1972;783-791
18. Cohen S., Chiles J., MacNaughton A. Weight gain associated with clozapine [see comments]. Am. J. Psychiatry. 147:1990;503-504
19. Cohen S., Fitzgerald B., Okos A., Khan S., Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J. Clin. Psychiatry. 64:2003;60-62
20. Colombel A., Charbonnel B. Weight gain and cardiovascular risk factors in the post-menopausal women. Hum. Reprod. 12:1997;134-145
21. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes Diabetes Care. 27:2004;596-601
22. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346:2002;16-22
23. Davidson S., Judd F., Jolley D., Hocking B., Thompson S., Hyland B. Cardiovascular risk factors for people with mental illness. Aust. N. Z. J. Psychiatry. 35:2001;196-202
24. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 26:2000;903-912
25. Domon S.E., Webber J.C. Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J. Child Adolesc. Psychopharmacol. 11:2001;285-288
26. Domon S.E., Cargile C.S. Quetiapine-associated hyperglycemia and hypertriglyceridemia. J. Am. Acad. Child Adolesc. Psychiatry. 41:2002;495-496
27. Dursun S.M., Szemis A., Andrews H., Reveley M.A. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J. Psychiatry Neurosci. 24:1999;453-455
28. Echevarria K.L., Hardin T.C., Smith J.A. Hyperlipidemia associated with protease inhibitor therapy. Ann. Pharmacother. 33:1999;859-863
29. Eder U., Mangweth B., Ebenbichler C., Weiss E., Hofer A., Hummer M., Kemmler G., Lechleitner M., Fleischhacker W.W. Association of olanzapine-induced weight gain with an increase in body fat. Am. J. Psychiatry. 158:2001;1719-1722
30. Expert Panel Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
31. Fleischhacker W.W., Stuppack C., Moser C., Schubert H., Hinterhuber H. Fluperlapine vs. haloperidol: a comparison of their neuroendocrinological profiles and the influence on serum lipids. Pharmacopsychiatry. 19:1986;111-114
32. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 287:2002;356-359
33. Gaulin B.D., Markowitz J.S., Caley C.F., Nesbitt L.A., Dufresne R.L. Clozapine-associated elevation in serum triglycerides. Am. J. Psychiatry. 156:1999;1270-1272
34. Ghaeli P., Dufresne R.L. Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy. 15:1995;382-385
35. Ghaeli P., Dufresne R.L. Serum triglyceride levels in patients treated with clozapine. Am. J. Health-Syst. Pharm. 53:1996;2079-2081
36. Goodnick P.J., Jerry J.M. Aripiprazole: profile on efficacy and safety. Exp. Opin. Pharmacother. 3:2002;1773-1781
37. Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 83:1999;25F-29F
38. Hadigan C. Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. Clin. Infect. Dis. 37:2003;S101-S104
39. Hagg S., Soderberg S., Ahren B., Olsson T., Mjorndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J. Clin. Psychiatry. 62:2001;843-848
40. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., Goff D.C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry. 157:2000;975-981
41. Hummer M., Kemmler G., Kurz M., Kurzthaler I., Oberbauer H., Fleischhacker W.W. Weight gain induced by clozapine. Eur. Neuropsychopharmacol. 5:1995;437-440
42. Itoh T., Horie S., Takahashi K., Okubo T. An evaluation of various indices of body weight change and their relationship with coronary risk factors. Int. J. Obes. Rel. Metab. Disord.: J. Int. Assoc. Study Obes. 20:1996;1089-1096
43. Jenkins D.J., Kendall C.W., Marchie A., Faulkner D.A., Wong J.M., de Souza R., Emam A., Parker T.L., Vidgen E., Lapsley K.G., Trautwein E.A., Josse R.G., Leiter L.A., Connelly P.W. Effects of a dietary portfolio of cholesterol-lowering foods vs. lovastatin on serum lipids and C-reactive protein. JAMA. 290:2003;502-510
44. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study [see comments]. [published erratum appears in Circulation 1998 May 19;97(19):1995] [see comments] Circulation. (97):1998;1029-1036
45. Jin H., Meyer J.M., Jeste D.V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry. 14:2002;59-64
46. Kingsbury S.J., Fayek M., Trufasiu D., Zada J., Simpson G.M. The apparent effects of ziprasidone on plasma lipids and glucose. J. Clin. Psychiatry. 62:2001;347-349
47. Kinon B.J., Basson B.R., Gilmore J.A., Tollefson G.D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry. 62:2001;92-100
48. Koro C.E., Fedder D.O., L'Italien G.J., Weiss S., Magder L.S., Kreyenbuhl J., Revicki D., Buchanan R.W. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch. Gen. Psychiatry. 59:2002;1021-1026
49. Kraus T., Haack M., Schuld A., Hinze-Selch D., Kuhn M., Uhr M., Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry. 156:1999;312-314
50. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 28:2003;519-526
51. Lamberti J.S., Bellnier T., Schwarzkopf S.B. Weight gain among schizophrenic patients treated with clozapine. Am. J. Psychiatry. 149:1992;689-690
52. Le Fevre P.D. Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism? Scott. Med. J. 46:2001;11-13
53. Leadbetter R., Shutty M., Pavalonis D., Vieweg V., Higgins P., Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am. J. Psychiatry. 149:1992;68-72
54. Lean M.E., Pajonk F.G. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 26:2003;1597-1605
55. Leonard P., Halley A., Browne S. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine. Ir. Med. J. 95:2002;119-120
56. Lund B.C., Perry P.J., Brooks J.M., Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch. Gen. Psychiatry. 58:2001;1172-1176
57. Manfredi R., Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidemic therapy with bezafibrate. J. Infect. 42:2001;181-188
58. Mantel-Teeuwisse A.K., Kloosterman J.M., Maitland-van der Zee A.H., Klungel O.H., Porsius A.J., de Boer A. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety. 24:2001;443-456
59. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Davis J.M., Kane J.M., Lieberman J., Schooler N.R. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr. Bull. 28:2002;5-16
60. Martin A., L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur. Child Adolesc. Psychiatry. 11:2002;129-133
61. Martinez J.A., Velasco J.J., Urbistondo M.D. Effects of pharmacological therapy on anthropometric and biochemical status of male and female institutionalized psychiatric patients. J. Am. Coll. Nutr. 13:1994;192-197
62. McIntyre R.S., McCann S.M., Kennedy S.H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. (comment) Can. J. Psychiatry-Rev. Can. Psychiatrie. 46:2001;273-281
63. Mefferd R.B., Labrosse E.H., Gawienowski A.M., Williams R.J. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. J. Nerv. Mental Dis. 127:1958;167-179
64. Melkersson K.I., Hulting A.L. Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacologia. 154:2001;205-212
65. Melkersson K.I., Hulting A.L., Brismar K.E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry. 61:2000;742-749
66. Meyer J.M. Effects of atypical antipsychotics on weight and serum lipid levels. J. Clin. Psychiatry. 62:2001;27-34. (discussion 40-21)
67. Meyer J.M. Novel antipsychotics and severe hyperlipidemia. J. Clin. Psychopharmacol. 21:2001;369-374
68. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J. Clin. Psychiatry. 63:2002;425-433
69. Meyer J.M. Cardiovascular illness and hyperlipidemia in patients with schizophrenia. Meyer J.M., Nasrallah H. Medical Illness and Schizophrenia. 2003;59-89 American Psychiatric Press, Washington, DC
70. Mortensen P.B., Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br. J. Psychiatry. 163:1993;183-189
71. Muller-Oerlinghausen B. A short survey on untoward effects of fluperlapine. Arzneim.-Forsch. 34:1984;131-134
72. Nasrallah, H.A., Perry, C.L., Love, E., Nasrallah, A.T., 2001 (December). Are there ethnic differences in hypertriglyceridemia secondary to olanzapine treatment. Poster presented at 40th ACNP Annual Meeting, Waikoloa, Hawaii.
73. Newcomer, J.W., Haupt, D.W., Melson, A.K., Schweiger, J.A., Cooper, B.J., 2001 (December). Plasma triglyceride levels in schizophrenia patients treated with antipsychotic medications. Abstract presented at 40th Annual ACNP Annual Meeting, Waikoloa, Hawaii.
74. Nguyen M., Murphy T. Olanzapine and hypertriglyceridemia. J. Am. Acad. Child Adolesc. Psychiatry. 40:2001;133
75. Orlandi F., Bamonti F., Dini M., Koch M., Jezequel A.M. Hepatic cholesterol synthesis in man: effect of diazepam and other drugs. Eur. J. Clin. Invest. 5:1975;139-146
76. Osby U., Correia N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 45:2000;21-28
77. Osser D.N., Najarian D.M., Dufresne R.L. Olanzapine increases weight and serum triglyceride levels. J. Clin. Psychiatry. 60:1999;767-770
78. Pi-Sunyer F.X. The obesity epidemic: pathophysiology and consequences of obesity. Obes. Res. 10:2002;97S-104S
79. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 60:2003;681-690
80. Rubins H.B. Triglycerides and coronary heart disease: implications of recent clinical trials. J. Cardiovasc. Risk. 7:2000;339-345
81. Sasaki J., Kumagae G., Sata T., Kuramitsu M., Arakawa K. Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis. 51:1984;163-169
82. Sasaki J., Funakoshi M., Arakawa K. Lipids and apolipoproteins in patients treated with major tranquilizers. Clin. Pharmacol. Ther. 37:1985;684-687
83. Serafetinides E.A., Colmore J.P., Rahhal D.K., Clark M.L. Trifluperidol in chronic male psychiatric patients. Behav. Neuropsychiatry. 3:1971;10-12
84. Serafetinides E.A., Collins S., Clark M.L. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. J. Nerv. Mental Dis. 154:1972;31-42
85. Shafique M., Khan I.A., Akhtar M.H., Hussain I. Serum lipids and lipoproteins in schizophrenic patients receiving major tranquilizers. J. Pak. Med. Assoc. 38:1988;259-261
86. Shaw J.A., Lewis J.E., Pascal S., Sharma R.K., Rodriguez R.A., Guillen R., Pupo-Guillen M. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J. Child Adolesc. Psychopharmacol. 11:2001;415-424
87. Sheitman B.B., Bird P.M., Binz W., Akinli L., Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels [letter]. Am. J. Psychiatry. 156:1999;1471-1472
88. Simpson G.M., Cooper T.B. The effect of three butyrophenones on serum cholesterol levels. Curr. Ther. Res., Clin. Experiment. 8:1966;249-255
89. Simpson G.M., Cooper T.B., Braun G.A. Further studies on the effect of butyrophenones on cholesterol synthesis in humans. Curr. Ther. Res., Clin. Experiment. 9:1967;413-418
90. Spivak B., Roitman S., Vered Y., Mester R., Graff E., Talmon Y., Guy N., Gonen N., Weizman A. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin. Neuropharmacol. 21:1998;245-250
91. Spivak B., Lamschtein C., Talmon Y., Guy N., Mester R., Feinberg I., Kotler M., Weizman A. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin. Neuropharmacol. 22:1999;98-101
92. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256:1986;2823-2828
93. Stoner S.C., Dubisar B.M., Khan R., Farrar C.D. Severe hypertriglyceridemia associated with olanzapine. J. Clin. Psychiatry. 63:2002;948-949
94. Taylor D.M. Aripiprazole: a review of its pharmacology and clinical use. Int. J. Clin. Pract. 57:2003;49-54
95. Umbricht D.S., Pollack S., Kane J.M. Clozapine and weight gain. J. Clin. Psychiatry. 55:1994;157-160. (Suppl.)
96. Vaisanen K., Rimon R., Raisanen P., Viukari M. A controlled double-blind study of haloperidol versus thioridazine in the treatment of restless mentally subnormal patients. Serum levels and clinical effects. Acta Psychiatr. Belg. 79:1979;673-685
97. Vampini C., Steinmayr M., Bilone F., Cominacini L., Robotti C.A. The increase of plasma levels of triglyceride during clozapine treatment: a case report. Neuropsychopharmacology. 10:1994;249s
98. Villablanca A.C., McDonald J.M., Rutledge J.C. Smoking and cardiovascular disease. Clin. Chest Med. 21:2000;159-172
99. Weiden P.J., Daniel D.G., Simpson G.M., Romano S.J. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J. Clin. Psychopharm. 23:2003;1-6
100. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Safety. 24:2001;59-73
101. Wetterling T. Hyperlipidemia-side-effect of the treatment with an atypical antipsychotic (zotepine)? Psychiatr. Prax. 29:2002;438-440
102. Wirshing D.A., Spellberg B.J., Erhart S.M., Marder S.R., Wirshing W.C. Novel antipsychotics and new onset diabetes. Biol. Psychiatry. 44:1998;778-783
103. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., Wirshing W.C. The effects of novel antipsychotics on glucose and lipid levels. J. Clin. Psychiatry. 63:2002;856-865
104. Wu G., Dias P., Chun W., Li G., Kumar S., Singh S. Hyperglycemia, hyperlipemia, and periodic paralysis: a case report of new side effects of clozapine. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 24:2000;1395-1400
105. Zimmermann U., Kraus T., Himmerich H., Schuld A., PollmAcher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J. Psychiatr. Res. 37:2003;193-220